Maureen Howard
21Patents
5h-index
28Co-inventors
69Inventor score
Filing activity: Mar 24, 1995 → Feb 3, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5837232A | Use of an interleukin-10 antagonist to treat a B cell mediated autoimmune disorder | Emerging Cross-Sectional Technologies | 18 | Expired |
| US9623079B2 | Methods for achieving therapeutically effective doses of anti-CD47 agents for treating cancer | Emerging Cross-Sectional Technologies | 13 | Active |
| US10301387B2 | Methods for achieving therapeutically effective doses of anti-CD47 agents | Emerging Cross-Sectional Technologies | 11 | Active |
| US11136391B2 | Methods for treating cancer by achieving therapeutically effective doses of anti-CD47 antibody | Emerging Cross-Sectional Technologies | 6 | Active |
| US6207155A | Method of eosinophil depletion with antibody to CCR 3 receptor | Human Necessities | 5 | Expired |
| US5837293A | Use of interleukin-10 analogs for antagonists to treat endotoxin- or superantigen-induced toxicity | Emerging Cross-Sectional Technologies | 5 | Expired |
| US7442512B2 | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors | Physics | 4 | Expired |
| US6171590A | Chemokine receptor peptide for inducing an immune response | Human Necessities | 4 | Expired |
| US11518806B2 | Methods for treating cancer by achieving therapeutically effective doses of anti-CD47 antibody | Emerging Cross-Sectional Technologies | 4 | Active |
| US11603404B2 | Methods for treating cancer by achieving therapeutically effective doses of anti-CD47 antibody | Emerging Cross-Sectional Technologies | 2 | Active |
| US5833976A | Use of interleukin-10 (IL-10) to treat endotoxin- or superantigen-induced toxicity | Emerging Cross-Sectional Technologies | 2 | Expired |
| US7253007B2 | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors | Physics | 2 | Expired |
| US7678891B2 | Antibodies that bind CCX-CKR2 | Physics | 1 | Active |
| US8637043B2 | Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof | Emerging Cross-Sectional Technologies | 0 | Active |
| US7777009B2 | Compositions for detecting and treating diseases and conditions related to chemokine receptors | Physics | 0 | Active |
| US7413866B2 | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors | Physics | 0 | Expired |
| US12258399B2 | Methods for achieving therapeutically effective doses of anti-CD47 agents | Emerging Cross-Sectional Technologies | 0 | Active |
| US11104731B2 | Compositions for achieving therapeutically effective doses of anti-CD47 agents | Emerging Cross-Sectional Technologies | 0 | Active |
| US7871619B2 | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors | Physics | 0 | Active |
| US12258403B2 | Methods for treating myeloma by achieving therapeutically effective doses of anti-CD47 antibody | Emerging Cross-Sectional Technologies | 0 | Active |
| US7361329B2 | Compositions for inducing an immune response | Human Necessities | 0 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.